聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎引发的1型糖尿病。
Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.
作者信息
Tanaka Junichirou, Sugimoto Kazushi, Shiraki Katsuya, Beppu Tetsuya, Yoneda Kentarou, Fuke Hiroyuki, Yamamoto Norihiko, Ito Keiichi, Takei Yoshiyuki
机构信息
Department of Gastroenterology, Mie University School of Medicine, Tsu.
出版信息
Intern Med. 2008;47(8):747-9. doi: 10.2169/internalmedicine.47.0653. Epub 2008 Apr 16.
A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C. Pancreatic autoantibody tests were negative before the start of therapy, but a significant increase in glutamic acid decarboxylase (GAD) antibody titer was seen after 24 weeks of treatment. Six months after the onset of type 1 diabetes mellitus, the patient continues to receive 40 units of insulin daily. The clinical course suggested that recombinant alpha-2b peginterferon plus ribavirin provoked type 1 diabetes mellitus, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.
一名51岁男性在接受重组α-2b聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎24周后发生了1型糖尿病。治疗开始前胰腺自身抗体检测为阴性，但治疗24周后谷氨酸脱羧酶（GAD）抗体滴度显著升高。1型糖尿病发病6个月后，该患者继续每日接受40单位胰岛素治疗。临床病程提示重组α-2b聚乙二醇干扰素联合利巴韦林诱发了1型糖尿病，因此，对于干扰素治疗的候选患者，治疗前和治疗期间应检测胰腺自身抗体及空腹血糖水平。
Zotero 插件